L W de Boo, K Jóźwiak, N D Ter Hoeve, P J van Diest, M Opdam, Y Wang, M K Schmidt, V de Jong, S Kleiterp, S Cornelissen, D Baars, R H T Koornstra, E D Kerver, T van Dalen, A D Bins, A Beeker, S M van den Heiligenberg, P C de Jong, S D Bakker, R C Rietbroek, I R Konings, R Blankenburgh, R M Bijlsma, A L T Imholz, N Stathonikos, W Vreuls, J Sanders, E H Rosenberg, E A Koop, Z Varga, C H M van Deurzen, A L Mooyaart, A Córdoba, E Groen, J Bart, S M Willems, V Zolota, J Wesseling, A Sapino, E Chmielik, A Ryska, A Broeks, A C Voogd, E van der Wall, S Siesling, R Salgado, G M H E Dackus, M Hauptmann, M Kok, S C Linn
BACKGROUND: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported...
March 6, 2024: ESMO Open